Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Autologous STEM Cell Collection after Daratumumab, Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Thalidomide and Dexamethasone in NEWLY Diagnosed Multiple Myeloma: A Real-Life Monocentric Italian Experience

Francesca Fazio, Mauro Passucci, Jacopo Micozzi, Silvia Sorella, Chiara Lisi, David Fanciullo, Alfonso Piciocchi, Mahnaz Shafii Bafti, Maurizio Martelli, Maria Gozzer, Maria Teresa Petrucci

Blood (2023) 142 (Supplement 1): 6651.

https://doi.org/10.1182/blood-2023-188780

Published: 2023

Journal Articles

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Blood (2023) 142 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2023-189300

Published: 2023

Journal Articles

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Emilio Iannitto, Monica Balzarotti, Maurizio Martelli, Pier Luigi Zinzani, Alessandra Tucci, Alice Di Rocco, Federica Cavallo, Sara Usai, Anna Guidetti, Emanuele Ravano, Franceso Merli, Barbara Botto, Matteo Pelosini, Cristina Tecchio, Michele Spina, Enrico Derenzini, Silvia Finotto, Brunella Mola, Antonio Pinto, Manuela Zanni, Roberta Battistini, Stefan Hohaus, Irene Dogliotti, Guido Gini, Vittorio Ruggero Zilioli, Sonya De Lorenzo, Anna Dodero, Alessandro Broccoli, Alessandro Maggi, Clara Mannarella, Annalisa Chiarenza, Domenico Pastore, Pellegrino Musto, Caterina Stelitano, Francesco Di Raimondo, Nicola Cascavilla, Nicola Di Renzo, Marilena Salerno, Renato Scalone, Luca Nassi, Attilio Guarini, Caterina Patti, Vita Polizzi, Gabriella Amato, Giovannino Ciccone, Andrea Evangelista, Agostino La Porta, Angelo Genua, Donato Mannina, Ciro Maria Improta, Alessandro Re, Fabrizio Lo Presti, Rosalba Donatella Calogero, Maurizio Musso, Ugo Consoli

Blood (2023) 142 (Supplement 1): 986.

https://doi.org/10.1182/blood-2023-178197

Published: 2023

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

Health-Related Quality of Life Profile and Symptom Burden of Patients with Aggressive B-Cell Lymphomas Just before CAR-T-Cell Therapy: A Real-World Study By the Gimema

Blood (2023) 142 (Supplement 1): 7384.

https://doi.org/10.1182/blood-2023-180012

Published: 2023

Journal Articles

30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study

Enrique M Ocio, Aurore Perrot, Philippe Moreau, Maria-Victoria Mateos, Sara Bringhen, Joaquin Martinez-Lopez, Lionel Karlin, Igor Wolfgang Blau, Song-Yau Wang, Maurizio Martelli, Corina Oprea, Yvonne Dong, Ercem Kodas, Jesus San Miguel

Blood (2023) 142 (Supplement 1): 6717.

https://doi.org/10.1182/blood-2023-175020

Published: 2023

Journal Articles

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Emanuele Zucca, Luca Ceriani, Andrew S. Davies, Giovannino Ciccone, Umberto Ricardi, Alice Di Rocco, Iryna Kryachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Sara Usai, Luca Arcaini, Elsa Pennese, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Franceso Merli, Wei Li Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Stefano Volpetti, Carla Minoia, Michele Spina, Alexander Fossa, George Mikhaeel, Kate Cwynarski, Andrea Janikova, Yana Stepanishyna, Mats Jerkeman, Andreas Huettmann, Maria Gomes da Silva, Don A. Stevens, Sally F Barrington, Bogdan Małkowski, Ur Metser, Annibale Versari, Stephane Chauvie, Oreste Bagni, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Letizia Deantonio, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Franco Cavalli, Peter Johnson, Maurizio Martelli

Blood (2023) 142 (Supplement 1): 1718.

https://doi.org/10.1182/blood-2023-174093

Published: 2023

Journal Articles

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Blood (2022) 140 (Supplement 1): 7147–7149.

https://doi.org/10.1182/blood-2022-165338

Published: 2022

Journal Articles

Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines

Monia Marchetti, Annalisa Chiappella, Maria Guarino, Giorgia Gobbi, Massimo Martino, Andrés J.M. Ferreri, Luca Fumagalli, Riccardo Saccardi, Mauro Montanari, Maurizio Martelli, Francesco Merli, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 5056–5057.

https://doi.org/10.1182/blood-2022-165125

Published: 2022

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Blood (2022) 140 (Supplement 1): 6623–6626.

https://doi.org/10.1182/blood-2022-157761

Published: 2022

Journal Articles

Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

Blood (2022) 140 (Supplement 1): 9375–9377.

https://doi.org/10.1182/blood-2022-159949

Published: 2022

Journal Articles

Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study

Giovanni Manfredi Assanto, Alice Di Rocco, Francesco Malfona, Marcello Capriata, Ilaria Del Giudice, Luigi Petrucci, Paola Girardi, Gianna Maria D'elia, Maurizio Martelli, Giuseppe Gentile, Alessandra Micozzi, Alessandro Pulsoni

Blood (2022) 140 (Supplement 1): 3566–3567.

https://doi.org/10.1182/blood-2022-164544

Published: 2022

Journal Articles

Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

Blood (2022) 140 (Supplement 1): 9226–9227.

https://doi.org/10.1182/blood-2022-162416

Published: 2022

Journal Articles

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Blood (2022) 140 (Supplement 1): 9688–9690.

https://doi.org/10.1182/blood-2022-157914

Published: 2022

Journal Articles

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1705–1707.

https://doi.org/10.1182/blood-2022-157393

Published: 2022

Journal Articles

Venous Thromboembolism (VTE) in Patients with Hodgkin Lymphoma: Retrospective Evaluation of Throly and Khorana Risk Scores

Giovanni Manfredi Assanto, Martina Salvatori, Sara Pontecorvo, Natalia Cenfra, Gianna Maria D'elia, Giorgia Annechini, Maurizio Martelli, Alessandro Pulsoni, Ilaria Del Giudice, Antonio Chistolini

Blood (2022) 140 (Supplement 1): 12018–12019.

https://doi.org/10.1182/blood-2022-164529

Published: 2022

Journal Articles

Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

Roberto Latagliata, Ida Carmosino, Ambra Di Veroli, Emilia Scalzulli, Gioia Colafigli, Maria Cristina Scamuffa, Alessio Di Prima, Cinzia De Gregoris, Sara Pepe, Marco Mancini, Giulio Trapè, Maurizio Martelli, Robin Foa, Massimo Breccia

Blood (2021) 138 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2021-151220

Published: 2021

Journal Articles

Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy

Francesca Fazio, Alice Di Rocco, Tommaso Za, Valeria Tomarchio, Angela Rago, Alfonso Piciocchi, Tommaso Caravita di Toritto, Ombretta Annibali, Valerio De Stefano, Robin Foa, Maurizio Martelli, Maria Teresa Petrucci

Blood (2021) 138 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2021-149547

Published: 2021

Journal Articles

Long-Term Treatment of Hairy Cell Leukemia Patients with Interferon: Clinical and Molecular Aspects

Giovanni Manfredi Assanto, MD, Costantino Riemma, MD, Francesco Malaspina, MD, Salvatore Perrone, MD, Maria Lucia De Luca, MD, Giorgia Annechini, MD, Gianna Maria D'elia, Maurizio Martelli, MD, Robin Foà, MD, Enrico Tiacci, Alessandro Pulsoni, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-136660

Published: 2020

Journal Articles

Mantle CELL Lymphoma (MCL) in Elderly Patients (PTs): The Experience in Real-Life of Rete Ematologica Laziale Linfomi (RELLI)

Alessandro Alessandro Andriani, Gabriella Tomei, Cristiano Tesei, Ombretta Annibali, Cristina Andrizzi, Fiammetta Natalino, MD, Paola Anticoli Borza, Elisabetta Abruzzese, MD, Elena Maiolo, Alice Di Rocco, Luigi Petrucci, MD, Maria Cantonetti, Fioretta Palombi, Natalia Cenfra, MD, Luigi Rigacci, MD, Stefan Hohaus, MD, Maurizio Martelli, MD, N. Christina Cox, MD

Blood (2019) 134 (Supplement_1): 5257.

https://doi.org/10.1182/blood-2019-124696

Published: 2019

NARROW

Autologous STEM Cell Collection after Daratumumab, Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Thalidomide and Dexamethasone in NEWLY Diagnosed Multiple Myeloma: A Real-Life Monocentric Italian Experience

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Health-Related Quality of Life Profile and Symptom Burden of Patients with Aggressive B-Cell Lymphomas Just before CAR-T-Cell Therapy: A Real-World Study By the Gimema

30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines

Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study

Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Venous Thromboembolism (VTE) in Patients with Hodgkin Lymphoma: Retrospective Evaluation of Throly and Khorana Risk Scores

Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy

Long-Term Treatment of Hairy Cell Leukemia Patients with Interferon: Clinical and Molecular Aspects

Mantle CELL Lymphoma (MCL) in Elderly Patients (PTs): The Experience in Real-Life of Rete Ematologica Laziale Linfomi (RELLI)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only